NCT02909088 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE
A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol. 2014 Jan-Feb;37(1):26-30. doi: 10.1097/WNF.0000000000000017.
Maguire G, Franklin D, Vatakis NG, Morgenshtern E, Denko T, Yaruss JS, Spotts C, Davis L, Davis A, Fox P, Soni P, Blomgren M, Silverman A, Riley G
Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: the EXamining Pa
Maguire GA, Riley GD, Franklin DL, Gottschalk LA
Risperidone for the treatment of stuttering. J Clin Psychopharmacol. 2000 Aug;20(4):479-82.
Maguire GA, Riley GD, Franklin DL, Maguire ME, Nguyen CT, Brojeni PH
Olanzapine in the treatment of developmental stuttering: a double-blind, placebo-controlled trial. Ann Clin Psychiatry. 2004 Apr-Jun;16(2):63-7.
Maguire GA, Riley GD, Yu BP
A neurological basis of stuttering? Lancet Neurol. 2002 Nov;1(7):407. Review.
Maguire GA, Yu BP, Franklin DL, Riley GD
Alleviating stuttering with pharmacological interventions. Expert Opin Pharmacother. 2004 Jul;5(7):1565-71. Review.
Riley J, Riley G, Maguire G
Subjective Screening of Stuttering severity, locus of control and avoidance: research edition. J Fluency Disord. 2004;29(1):51-62.

An Open-label Study to Evaluate the Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).

Clinical trial NCT02909088 - References